These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24970847)

  • 1. One more step toward understanding the immune response to norovirus.
    Lee BE; Pang XL
    J Infect Dis; 2014 Dec; 210(11):1691-2. PubMed ID: 24970847
    [No Abstract]   [Full Text] [Related]  

  • 2. High serum levels of norovirus genotype-specific blocking antibodies correlate with protection from infection in children.
    Malm M; Uusi-Kerttula H; Vesikari T; Blazevic V
    J Infect Dis; 2014 Dec; 210(11):1755-62. PubMed ID: 24970849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of homologous and cross-reactive GII.4-specific blocking antibodies in children after GII.4 New Orleans norovirus infection.
    Blazevic V; Malm M; Vesikari T
    J Med Virol; 2015 Oct; 87(10):1656-61. PubMed ID: 25946711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of antibodies against GII.4 norovirus among children in Pune, India.
    Kulkarni R; Lole K; Chitambar SD
    J Med Virol; 2016 Sep; 88(9):1636-40. PubMed ID: 26868418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Functional Norovirus Antibody Responses by Blocking Assay in Mice.
    Malm M; Tamminen K; Blazevic V
    Methods Mol Biol; 2016; 1403():259-68. PubMed ID: 27076135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses against norovirus GII.4 virus-like particles in mice.
    Ushijima H; Machida S; Nomura A; Khamrin P; Tran DN; Nomura H; Hayakawa S
    Acta Virol; 2016; 60(4):339-346. PubMed ID: 27928912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norovirus immunity and the great escape.
    Debbink K; Lindesmith LC; Donaldson EF; Baric RS
    PLoS Pathog; 2012; 8(10):e1002921. PubMed ID: 23093932
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of the homo- and heterotypic immune responses after natural norovirus infection.
    Rockx B; Baric RS; de Grijs I; Duizer E; Koopmans MP
    J Med Virol; 2005 Nov; 77(3):439-46. PubMed ID: 16173019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
    Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
    Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norovirus GII.4 antibodies in breast milk and serum samples: their role preventing virus-like particles binding to their receptors.
    Khodayar-Pardo P; Martínez-Costa C; Carmona-Vicente N; Buesa J
    Pediatr Infect Dis J; 2014 Jun; 33(6):554-9. PubMed ID: 24830517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of rabbit antibodies raised against
    Kulkarni R; Lole K; Chitambar SD
    Indian J Med Res; 2017 Dec; 146(6):788-790. PubMed ID: 29664039
    [No Abstract]   [Full Text] [Related]  

  • 12. The evolution of norovirus, the "gastric flu".
    Lopman B; Zambon M; Brown DW
    PLoS Med; 2008 Feb; 5(2):e42. PubMed ID: 18271623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noroviruses: epidemiology, immunity and prospects for prevention.
    Pringle K; Lopman B; Vega E; Vinje J; Parashar UD; Hall AJ
    Future Microbiol; 2015; 10(1):53-67. PubMed ID: 25598337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Norovirus infections and seroprevalence of genotype GII.4-specific antibodies in a Spanish population.
    Carmona-Vicente N; Fernández-Jiménez M; Ribes JM; Téllez-Castillo CJ; Khodayar-Pardo P; Rodríguez-Diaz J; Buesa J
    J Med Virol; 2015 Apr; 87(4):675-82. PubMed ID: 25655810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immune responses against norovirus infections of children.
    Iritani N; Seto T; Hattori H; Natori K; Takeda N; Kubo H; Yamano T; Ayata M; Ogura H; Seto Y
    J Med Virol; 2007 Aug; 79(8):1187-93. PubMed ID: 17597489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.
    Malm M; Tamminen K; Vesikari T; Blazevic V
    Mol Immunol; 2016 Oct; 78():27-37. PubMed ID: 27573255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The formation of P particle increased immunogenicity of norovirus P protein.
    Tan M; Jiang X
    Immunology; 2012 May; 136(1):28-9. PubMed ID: 22257239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Norovirus Regulation by Host and Microbe.
    Baldridge MT; Turula H; Wobus CE
    Trends Mol Med; 2016 Dec; 22(12):1047-1059. PubMed ID: 27887808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Norovirus vaccine development: next steps.
    Atmar RL; Estes MK
    Expert Rev Vaccines; 2012 Sep; 11(9):1023-5. PubMed ID: 23151158
    [No Abstract]   [Full Text] [Related]  

  • 20. Isolation of cross-reactive human monoclonal antibodies that prevent binding of human noroviruses to histo-blood group antigens.
    Higo-Moriguchi K; Shirato H; Someya Y; Kurosawa Y; Takeda N; Taniguchi K
    J Med Virol; 2014 Apr; 86(4):558-67. PubMed ID: 24026909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.